1 / 9

Aging Cognition Evaluation

Aging Cognition Evaluation. A Unique Opportunity in understanding age related disorders. Improve understanding of the biology of memory disorder with concurrently collected serial: Cognitive data Biological samples Clinical events Potential applications across other pathologies

elina
Télécharger la présentation

Aging Cognition Evaluation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aging Cognition Evaluation A Unique Opportunity in understanding age related disorders

  2. Improve understanding of the biology of memory disorder with concurrently collected serial: • Cognitive data • Biological samples • Clinical events • Potential applications across other pathologies • Discover predictive biomarkers

  3. Objectives • Establish robust baseline cognition score • Identify meaningful changes in cognition • Follow cognition deficits and rate of change • Correlate changes in cognition score with changes in biology • Identify well characterized patients for further evaluation

  4. Outputs BIOLOGICAL • Genomic DNA • RNA from PAXGene • PBMCs ~4ml • Serum 0.5ml • Plasma 0.5ml • Urine 5ml • CSF 0.5ml (subpopulation) DEMOGRAPHIC • Family History • Current Meds • Ethnic History • Education • Smoking • Alcohol • Clinical events PSYCHOMETRIC • Semantic memory • Working memory • Executive function • Concentration • Response speed • MMSE

  5. 6-monthly serial follow-up of up to 5000 healthy subjects >60 y/o. • Collection of biological fluid samples including CSF (subpopulation) with simultaneous clinical and cognition evaluations using a CDR cognition battery at each 6 monthly visit. Protocol

  6. The ACE Solution: identify MCI using… …evidence of progressive cognitive decline

  7. 6 Monthly report to subject

  8. Protocol design Age 60-75 Able to present for a blood draw every 6 months Generally healthy Cognitively normal Cognition diminished Cognition diminished 6 months 6 months Cognition normal Cognition Battery Con Meds Con Diagnoses Blood Draw Spinal Tap (subpopulation) 6 months V.2 SCR. V.1 6 months Controls 6 months Consent CDR Cognition Battery training Con Meds Con Diagnoses Family history ECG Other tests Cognition Battery Con Meds Con Diagnoses Blood Draw Spinal Tap (subpopulation)

  9. Protocol design Contd: * Subpopulation ** Training

More Related